Locus Forms Research Collaboration With Novartis

Locus Pharmaceuticals (Locus) has entered into a research collaboration with Novartis. As per the deal, Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’s select therapeutic areas.

Driven by computational protein modeling and FBDD technology, Locus technology supports discovery of novel target-selective drug molecules. The technology platform is broadly applicable to many target classes including, but not limited to kinases, proteases, and receptors.

Joan Lau, president of Locus, said: “We are very excited about the opportunity to work with Novartis to enhance their drug discovery efforts using the Locus technology.”

Locus, a privately held drug discovery and development biotechnology company, creates novel therapeutics using its patented drug design technology. Locus has entered into several drug discovery collaboration projects with pharmaceutical partners, and built a pipeline of early drug development assets for cancer and inflammatory indications.